Shirlynn Chen

6828301, Dec 7, 2004

Feb 4, 2003

10/357919

Shirlynn Chen - Somers NY
Xiaohui Mei - Highland Mills NY

Boehringer Ingelheim International GmbH - Ingelheim

A61K 4718

514 9, 514 10, 514 11, 514 18, 514 19

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.

7157424, Jan 2, 2007

Mar 23, 2004

10/807023

Shirlynn Chen - Somers NY, US
Xiaohui Mei - Highland Mills NY, US
Zeren Wang - Southbury CT, US

Boehringer Ingelheim International GmbH - Ingelhein

A61K 38/12
A61K 38/00
A61K 38/02
A61K 31/4709

514 11, 514 2, 514 9, 514312

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions are lipid based systems and comprise the hepatitis C viral protease inhibitor together with at least one pharmaceutically acceptable amine, at least one pharmaceutically acceptable base, at least one pharmaceutically acceptable oil and optionally one or more additional ingredients.

8598183, Dec 3, 2013

Sep 23, 2011

13/241551

Rolf-Stefan Brickl - Warthausen, DE
Shirlynn Chen - Somers NY, US
Jihchin Chung - Princeton Junction NJ, US
Mayur Suryakant Dudhedia - Brookfield CT, US
Danping Li - Middlebury CT, US
Zhi-Hui Lu - Newtown CT, US
Siddharthya Mujumdar - Auburndale MA, US
Chitra Telang - Brookfield CT, US
Richard J. Varsolona - Scotch Plains NJ, US
Zeren Wang - Southbury CT, US

Boehringer Ingelheim International GmbH - Ingelheim am Rhein

C07D 235/04

514256, 544333

This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:.

20020115690, Aug 22, 2002

Oct 30, 2001

10/020492

Shirlynn Chen - Somers NY, US
Jocelyn Gunn - Hamden CT, US

A61K031/4433
A61K031/366

514/336000, 514/457000, 514/460000

A microemulsion of pyranone protease inhibitor compounds that is substantially free of alcohol and propylene glycol comprising a pyranone protease inhibitor, one or more pharmaceutically acceptable surfactants, and a polyethylene glycol solvent having a mean molecular weight of greater than 300 but lower than 600, and a lipophilic component comprising medium chain mono- and di-glycerides, and optionally a basic amine.

20040033959, Feb 19, 2004

Jul 16, 2003

10/620408

Shirlynn Chen - Somers NY, US
Xiaohui Mei - Highland Mills NY, US

Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT

A61K038/06

514/018000

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.

20040138109, Jul 15, 2004

Sep 16, 2003

10/663220

Shirlynn Chen - Somers NY, US
Jens Croenlein - Mittelbiberach, DE
Gerhard Nehmiz - Biberach, DE
Gerhard Steinmann - Erbach-Bach, DE
Jocelyn Gunn - Hamden CT, US
Phuong Costa - Danbury CT, US

A61K038/12
A61K038/05

514/009000, 514/018000, 514/312000

Disclosed are oral pharmaceutical compositions, kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein the following Compound (1), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range: Also disclosed are the use of a compound of formula (1), or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.

20060068007, Mar 30, 2006

Sep 16, 2005

11/228123

Jinjiang Li - New Milford CT, US
Shirlynn Chen - Somers NY, US
George Gereg - Bethel CT, US
Mariotte Corson - Newtown CT, US

Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT

A61K 9/20
A61K 31/355

424464000, 514458000

This invention generally refers to a novel class of surfactant-like material that promotes the solubility of poorly soluble compounds.

20140057928, Feb 27, 2014

Oct 30, 2013

14/067218

Rolf-Stefan BRICKL - Warthausen, DE
Shirlynn CHEN - Somers NY, US
Jihchin CHUNG - Princeton Junction NJ, US
Mayur Suryakant DUDHEDIA - Brookfield CT, US
Danping LI - Middlebury CT, US
Zhi-Hui LU - Newtown CT, US
Siddharthya MUJUMDAR - Basel, CH
Chitra TELANG - Brookfield CT, US
Richard J. VARSOLONA - Scotch Plains NJ, US
Zeren WANG - Southbury NY, US

BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim am Rhein

C07D 403/14

514256, 544333

This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: